Is Thymosin Alpha-1 Legal in Michigan? How to Access It Legally
HealthRX.com
No FDA-approved thymosin alpha-1 product exists in the US
Key numbers
- 4 yes and 17 noFDA advisory committee vote on compounding thymosin alpha-1 (free base and acetate), December 4, 2024Source: fda.gov, as cited Nov 7, 2026
- 1.6 mgDose on Italy's Zadaxin label; no US-approved dose existsSource: fda.gov, as cited Nov 7, 2026
- risk ratio 0.72Cochrane 2026 review of hepatitis B trials: risk of serious adverse events versus comparison treatments, low-certainty evidenceSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- FDA approval / None. A Drugs@FDA search found no US marketing application [1]
- FDA bulks list, state-licensed pharmacies / In none of the three categories (list updated May 14, 2026) [2]
- FDA bulks list, outsourcing facilities / Category 3, nominated without adequate support (March 21, 2025) [3]
- Advisory committee vote / 4 yes, 17 no on the free base and the acetate, December 4, 2024 [4]
- HHS peptide policy / Not one of the six peptides in the October 2026 draft [5]
- Approved outside the US / Italy, India, Hong Kong [1]
What is its FDA status?
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence [1]. A Drugs@FDA search found no US marketing application for thymosin alpha-1; it is not FDA-approved [1]. It holds four US orphan drug designations, but orphan designation is a separate process and is not an approval [1].
FDA's December 2024 review lists approvals in Italy, as an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B in adults with compensated liver disease and virus replication, and in Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
Can a US pharmacy compound it?
FDA's list of bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, places thymosin alpha-1 in none of its three categories [2]. On the separate list for outsourcing facilities, updated March 21, 2025, it is category 3, "nominated without adequate support" [3]. FDA's category 1 policy, under which it generally does not act against compounders who meet the conditions, does not apply to it [2][3]. No FDA or HHS action allowing compounding of thymosin alpha-1 was found.
FDA's page on bulk substances that may raise significant safety risks (content dated April 22, 2026) lists thymosin alpha-1 in the "nominated but withdrawn" table: it had been in category 2 until the nominators withdrew [6]. FDA's concerns remain posted, including "significant risk for immunogenicity for certain routes of administration" and safety information "inadequate for the agency to sufficiently understand the extent of any safety issues" [6].
On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate [4]. Thymosin alpha-1 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, which names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [5].
Questions worth asking
What does the label say about dosing and safety?
No US-approved dose exists [1]. Italy's Zadaxin label says 1.6 mg powder is given subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. That label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and advises caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].
FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report adverse experiences "infrequent and mild" across more than 17 million post-marketing doses of Zadaxin; this is company-linked data [1]. A 2026 Cochrane review of hepatitis B trials found thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) [7]. The reviewers said they are "not sure" thymosin alpha-1 helps in chronic hepatitis B [7].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in Michigan?
Can a US compounding pharmacy make thymosin alpha-1?
Is thymosin alpha-1 approved in any country?
References
Show all 7 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.